The Oral Microbiome in Oral Cavity Cancer: Mechanisms of Carcinogenesis, Biomarkers, and Therapeutic Implications Authors: Katarzyna Pazdro-Zastawny, Marcin Kos, Anna Leszczyszyn, Tomasz Zawadzki, Kacper Pietruszka, Karolina Dorobisz Published: 2026 ABSTRACT AbstractPurpose of ReviewOral cavity cancer (OCC) is a significant clinical challenge within head and neck oncology. It is characterized by significant morbidity, high recurrence rates, and only modest improvements in long-term survival over recent decades. Recent advances in metagenomics and high-throughput sequencing have revealed that oral microbial dysbiosis contributes to tumorigenesis, highlighting the potential of microbiome-derived biomarkers for early detection and prognosis of OCC. The purpose of the work is to discuss oral microbiome alterations in OCC.Recent FindingsThe microbiome plays a crucial role in regulating the host's physiological, immunological, and metabolic functions. Changes in the composition of the microbiome can influence our health status of local diseases of the oral cavity and oropharynx, as well as systemic diseases. In recent years, the role of the oral microbiome in oral potentially malignant disorders progression and OCC development has been emphasized. Changes in the oral and gut microbiome can lead to the induction of chronic inflammation, modulation of the immune system, and the production of carcinogenic metabolites. Dysbiosis can lead to critical inflammatory responses and consequently contribute to neoplastic events. Microbiome-modulating therapies tailored to the patient's individual profile and aimed at improving cancer treatment outcomes are being introduced, including the introduction of antibiotics to reduce harmful bacteria.SummaryIdentification of new biomarkers in oral microbiota communities and development of therapeutic strategies in relation with oral microbiota in the future may be one of the pillars of the oral cancer diagnosis and treatment strategy. Oral cancer prevention protocols should include the improvement of oral hygiene as an element of the prevention and treatment of periodontitis. An introduction of microbiota-targeted interventions, including probiotics, prebiotics, and dietary strategies, may reduce the toxicity of radiotherapy, leading to improved patient outcomes.Keywords: Oral cavity cancer, Oral microbiome, Oral squamous cell carcinoma, Dysbiosis, Biomarkers, Periodontitis Introduction Oral cavity cancer (OCC) is a significant clinical challenge within head and neck oncology. It is categorized under head and neck cancer (HNC) and involves neoplastic lesions located in the oral cavity. OCC represents a biologically heterogeneous group of malignancies, predominantly oral squamous cell carcinoma (OSCC) [1, 2] arising from anatomically and functionally distinct subsites of the oral cavity. The anatomic OCC’s subsites are inner part of lips, anterior two-thirds of tongue, floor of mouth, buccal mucosa, hard palate, alveolar ridge and retromolar trigone [3, 4]. OCC is characterized by significant morbidity, high recurrence rates, and only modest improvements in long-term survival over recent decades [5]. It occurs relatively rarely (the sixteenth position in malignancy worldwide) [6]. Recent epidemiological data indicate diverging incidence trends for OCCSs in the United States and several European countries. While the incidence of most OCCs has declined, oral tongue cancers have shown an increasing trend, suggesting potential differences in underlying etiologic factors [3, 7–9]. The decreasing trend of OCC and the rising trend of oropharyngeal cancer and may be influenced by an increase in high-risk sexual behaviors and the growing prevalence of oral HPV infection [7]. The etiology of OCC is multifactorial and complex. Etiological factors include tobacco products usage in smoke and smokeless form, excess chronic alcohol consumption and betel quid usage [3, 10]. While HPV-positive oropharyngeal cancers typically occur in younger male non-smokers, OCCs remain primarily associated with traditional carcinogenic risk factors. The significance of HPV infection in oral potentially malignant lesions remains unclear. Oropharyngeal cancers—particularly those of the tonsils and the base of the tongue—are frequently HPV-driven, most commonly associated with HPV16. In contrast, HPV infection accounts for only 2–8% of OCCs [11]. Nevertheless, HPV may contribute to the development of potentially malignant precancerous squamous intraepithelial neoplasia and has been hypothesized to play a role in the progression of OSCC [12]. Low socioeconomic status, self-negligence, and lack of awareness, poor oral hygiene and peridontal disease may also be a contribute factors in OCC development [13]. Moreover, exposure to dust and heavy metals may lead to chronic inflammation or act as a carriers for other oncogenic compounds. Genetic mutations also promote the occurrence of OSCC through aberrant activation of oncogenic signaling and inactivation of suppressor signaling, promoting the transformation and uncontrolled proliferation of OSCC. However, these traditional risk factors do not fully explain individual differences in disease susceptibility, progression, or therapeutic outcomes. Increasing attention has therefore shifted toward host–environment interactions that may modulate carcinogenesis beyond genetic alterations alone. OCC is characterized by high clinical malignancy and diagnosed in significantly advanced stages [14, 15]. The outcome of OCC is strongly stage-dependent and is generally poorer than that of HPV-positive oropharyngeal cancers. In contrast to oropharyngeal cancer, HPV status does not reliably confer a prognostic advantage in OCC [16, 17]. The treatment of choice is surgery combined with radiochemotherapy without alterations in therapeutic results in the last few decades. Due to the still low survival rates in OCC, there is an urgent need for early detection and treatment and for reliable biomarkers to be introduced for diagnostics and predicting progression of OCC. Recent advances in metagenomics and high-throughput sequencing have revealed that microbial dysbiosis within the oral cavity may actively contribute to carcinogenic processes through chronic inflammation, immune evasion, and the production of carcinogenic metabolites. These findings have positioned the oral microbiome as a potential source of novel biomarkers and therapeutic targets in OCC [18]. Study Design and Methods The purpose of this study was to provide a brief and accurate review of the current knowledge on oral microbiome alterations in OCC, with a particular focus on mechanistic insights, interactions with HPV infection, and implications for radiotherapy and chemotherapy outcomes. We also outline future directions required to advance oral microbiome research toward clinically actionable applications in oral cavity cancer. A literature search was conducted in February 2026 using the PubMed/MEDLINE database. The following search terms and combinations were used: “oral microbiome”, “oral microbiota”, “oral cavity cancer”, “oral squamous cell carcinoma”, “oral cancer”, “dysbiosis”, “head and neck cancer”, “HPV”, “periodontitis”, “radiotherapy”, and “microbiome therapeutics”. The search primarily included articles published between January 2010 and February 2026, although selected earlier landmark studies of particular biological or clinical importance were also included. Only articles published in English were considered. Eligible studies included original research articles, clinical studies, translational studies, observational cohort studies, case–control studies, metagenomic and sequencing-based analyses, and relevant narrative or systematic reviews addressing oral microbiota alterations in OCC or related head and neck malignancies. Studies were excluded if they: did not focus on oral cavity cancer or oral microbiota, investigated non-oncologic oral diseases without relevance to carcinogenesis, lacked microbiological or molecular analysis, were conference abstracts, editorials, letters, or duplicate publications, involved insufficient methodological description or unavailable full text. The initial search identified 2549 publications. After title and abstract screening, studies not directly related to the scope of this review were excluded. Full-text assessment was subsequently performed, and 105 studies were ultimately included in the final synthesis. Reference lists of eligible articles were additionally screened to identify further relevant publications. Due to heterogeneity in study design, microbiome sampling methods, sequencing platforms, and analytical pipelines, a qualitative narrative synthesis was performed rather than a formal meta-analysis. Oral Microbiome Humans harbor a complex and dynamic microbial ecosystem that plays a fundamental role in maintaining physiological, immunological, and metabolic homeostasis. The microbiota comprises bacteria, archaea, fungi, viruses, and protozoa, while the microbiome additionally includes their collective genomes and environmental context [19, 20]. Through continuous host–microbe and microbe–microbe interactions, these communities contribute to epithelial integrity, immune regulation, and metabolic balance, thereby influencing both health and disease susceptibility. The oral microbiome is increasingly recognized as an active participant in the carcinogenic microenvironment, influencing epithelial integrity, inflammation, and immune signaling [21]. The oral microbiome is the second largest microbial ecosystem in the human body after the gut microbiome and consists of highly structured polymicrobial communities distributed across distinct ecological niches, including saliva, tongue, teeth surfaces, gingiva, buccal mucosa, and subgingival and supragingival biofilms [22–25]. It is composed of approximately 500–1000 bacterial species, as well as fungi, archaea, protozoa, and viruses. Each niche is characterized by specific environmental conditions such as oxygen availability, pH, and nutrient gradients, which shape microbial composition. For example, anaerobic taxa such as Fusobacterium and Prevotella dominate subgingival sites, whereas aerobic genera including Neisseria and Streptococcus are more prevalent on the tongue and buccal mucosa [26]. The oral microbiota is dominated by six major bacterial phyla—Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes, and Fusobacteriota—which collectively account for the vast majority of oral taxa [27–29]. Although relatively stable in healthy individuals, its composition is influenced by factors such as age, diet, oral hygiene, smoking, and systemic disease. In physiological conditions, these microbial communities exist in a balanced symbiotic relationship with the host, contributing to mucosal integrity and immune homeostasis. [27–29]. The remaining ~ 4% comprises less abundant phyla, including Euryarchaeota, Gracilibacteria (GN02), Chlamydiae, Chloroflexi, SR1, Synergistetes, Tenericutes, and Saccharibacteria (TM7) [30]. Table 1 shows composition of the human oral microbiota at the phylum level. Table 1Composition of the human oral microbiota at the phylum level (based on Deo et al [23])PhylumRepresentative generaRelative abundance in the oral microbiotaFirmicutesStreptococcus, Gemella, Eubacterium, Selenomonas, Abiotrophia, Granulicatella, Veillonella ~ 20–50%BacteroidetesPrevotella, Capnocytophaga, Porphyromonas, Bacteroides, Tannerella, Bergeyella ~ 10–30%ProteobacteriaNeisseria, Eikenella, Campylobacter, Haemophilus ~ 15–35%ActinobacteriaCorynebacterium, Rothia, Actinomyces, Microbacterium, Propionibacterium, Mycobacterium ~ 10–25%SpirochaetesTreponema < 1–5%FusobacteriotaFusobacterium, Leptotrichia ~ 5–15%Other phylaEuryarchaeota, Gracilibacteria (GN02), Chlamydiae, Chloroflexi, SR1, Synergistetes, Tenericutes, Saccharibacteria (TM7) ~ 4%Total (dominant phyla)- ~ 80–96% Composition of the human oral microbiota at the phylum level (based on Deo et al [23]) These dominant phyla are consistently present across individuals, although their relative abundance is influenced by age, oral hygiene, diet, and systemic health. In healthy hosts, these microbial communities coexist in a balanced ecosystem that supports mucosal integrity and immune homeostasis. Shifts in phylum composition—particularly the enrichment of Fusobacterium, Prevotella, and Porphyromonas—have been associated with oral dysbiosis. Functionally, the oral microbiota provides essential protective, immunological, and metabolic roles. Commensal microorganisms prevent pathogen overgrowth through competitive exclusion, modulate host immune responses to maintain tolerance and defense, and contribute to metabolic processes such as carbohydrate breakdown and nitrate metabolism [31]. In addition, they participate in maintaining acid–base balance within the oral cavity, thereby supporting enamel integrity and reducing susceptibility to dental caries. However, disturbances such as high-sugar diets or reduced salivary flow can disrupt this equilibrium, leading to ecological imbalance and microbial shifts. Overall, the oral microbiome represents a highly dynamic ecosystem that is essential for maintaining host homeostasis and metabolic stability, while remaining highly susceptible to environmental perturbations that may drive dysbiosis and disease development [32]. Oral–Gut Microbiota Axis Oral bacteria and their derivatives, including microbial-associated molecular patterns and extracellular vesicles, may translocate to the gastrointestinal tract through saliva, fecal–oral route and the bloodstream. They avoid mucosal defenses, co-work with local immune cells, and lead to disruption of epithelial integrity. Oral—gut microbiota axis is a pivotal pathway through which oral microbiota modulate systemic immunity. Oral diseases, antibiotics, or gastrointestinal conditions may lead to disruptions in oral and/or gut microbiota which subsequently may result in dysbiosis and promote systemic inflammation. The dissemination of oral microbes to the gut may aggravate various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer [33]. Periodontitis exacerbates gut inflammation in vivo promoting the expansion of pathobiont members of the oral microbiota, which favor colitis through colonization of the gut and also induction of migratory Th17 cells, forming a dual microbiome and immune mechanism connecting oral and gut well-being [34]. Dysbiosis Oral dysbiosis, characterized by a significant shift in the relative abundance of microbial communities, disrupts the physiological functions of the microbiome and contributes to disease development. Increasing evidence indicates that this imbalance plays a crucial role in a wide range of clinical conditions, both local and systemic. Dysbiosis has been implicated not only in oral diseases such as dental caries, gingivitis, and periodontitis, but also in systemic disorders, including cardiovascular, respiratory, neurodegenerative (e.g., Alzheimer’s disease), and metabolic diseases [35]. Bacterial communities inhabiting distinct ecological niches within the oral cavity interact synergistically to maintain oral homeostasis. Beyond local effects, the oral microbiota contributes to systemic health through complex host–microbe and microbe–microbe interactions. However, endogenous and exogenous factors may disrupt this equilibrium, leading to dysbiosis characterized by altered microbial composition and breakdown of the host–microbe balance. The oral microbiota can function as a stabilizer of microbial diversity, but under dysbiotic conditions it may also contribute to pathogenic processes. In particular, oral dysbiosis is associated with inflammatory oral diseases and may promote immune evasion, production of pro-inflammatory cytokines such as IL-6 and TNF-α, and microbial metabolites that influence oncogenic signaling pathways [36]. A strong association exists between chronic inflammation and the development of various human cancers, including OCC. Periodontitis, a chronic inflammatory condition accompanied by immune dysregulation, has been significantly linked to cancer initiation and progression. This relationship is supported by elevated levels of pro-inflammatory cytokines, including IL-1α, IL-1β, TNF-α, and IL-6, which contribute to tissue damage, genomic instability, and epigenetic alterations. These processes may promote apoptosis dysregulation, angiogenesis, and disruption of inflammatory signaling pathways. Moreover, bacterial species such as Fusobacterium nucleatum and Porphyromonas gingivalis can activate NF-κB, Toll-like receptor (TLR), and MAPK signaling pathways, sustaining chronic inflammation in oral epithelial cells and enhancing pro-tumorigenic responses [37]. Microbial dysbiosis, resulting from severe ecological disruption and habitat loss—particularly following complete tooth loss—may further contribute to the development of OCC. Microbial alterations have been proposed to represent either an early event in oncogenesis, potentially contributing to neoplastic transformation, or a later consequence of opportunistic colonization within the tumor microenvironment [38, 39]. Comparative analyses of the oral microbiome in patients with oral leukoplakia, proliferative leukoplakia, and OSCC have demonstrated a progressive shift toward dysbiosis during malignant transformation [40, 41]. These findings suggest that the oral microbiome is closely involved in carcinogenesis through the interplay of chronic inflammation, immune modulation, and microbial dysregulation. Its role appears to span the entire spectrum of cancer development, from early initiating events to tumor progression. Oral Microbiome and HPV infection Human papillomavirus (HPV) infection is strongly associated with the development of various mucosal cancers, particularly cervical and oropharyngeal malignancies, and is a well-established risk factor for carcinogenesis. The virus primarily infects undifferentiated, proliferating cells and initially establishes infection in the basal layer of stratified epithelia. The progression of HPV infection and the host immune response are influenced by multiple factors, including epithelial surface integrity, mucosal secretions, immune regulation, and the surrounding microbiological environment [42]. Approximately 36% of oropharyngeal and 24% of OSCCs are associated with HPV infection, most commonly HPV16 [43]. A high prevalence of HPV16 has been reported in both oral and oropharyngeal SCCs [44–47]. Distinct differences in gene expression and treatment sensitivity have been identified between HPV-positive and HPV-negative oropharyngeal cancers. HPV-positive tumors appear to demonstrate increased sensitivity to radiotherapy and favorable responses to cisplatin-based chemoradiotherapy [48, 49]. Although similar observations have occasionally been reported in oral cavity cancers, the available evidence remains limited and less consistent due to the substantially lower prevalence of HPV in these tumors. A complex interaction between HPV and oral microbiota exists, which may affect viral persistence, immune response, and tumor microenvironment. This interaction may influence disease progression, clinical outcomes, and the overall therapeutic approach to the patient [50]. Oral microbiota has emerged as become a promising biomarker in the detection of HPV and the assessment of disease progression [51, 52]. In a multicenter study of HNSCC patients with paired tumor samples, Chan et al. demonstrated that Fusobacterium abundance was associated with improved patient outcomes and better 3-year disease-specific survival. HPV infection rates ranged from 66.7% in non-smoking patients with early T-stage and early N-stage oropharyngeal SCC to 10.4% in oral SCC. HPV infection in non-oral cavity SCC, especially located in the oropharynx, was associated with advanced N stage and better survival outcomes [53]. Oral microbiota could play a role in disease progression, response to treatment, or recovery, highlighting its potential as a therapeutic target or biomarker [54]. The Role of the Oral Microbiome as a Potential Biomarker and Risk Factor for OCC In recent years, increasing attention has been given to the role of the oral microbiome in the progression of oral potentially malignant disorders and the development of OSCC. Microbial dysbiosis, including alterations in both the oral and gut microbiome, has been associated with chronic inflammation, immune modulation, and the production of carcinogenic metabolites. In patients with OSCC, significant shifts in microbial composition have been reported, including an increased abundance of Firmicutes and Synergistetes at the phylum level, and genera such as Fusobacterium, Prevotella, Porphyromonas, Parvimonas, and Peptostreptococcus. At the species level, Fusobacterium nucleatum and Porphyromonas gingivalis are frequently enriched, suggesting a pro-inflammatory and tumor-promoting microenvironment. Similar dysbiotic patterns have also been observed in head and neck squamous cell carcinoma (HNSCC), further supporting the association between microbial imbalance and cancer progression [55, 56]. Beyond descriptive associations, microbiota is increasingly recognized as an active participant in carcinogenesis through modulation of host cell proliferation and apoptosis, immune system regulation, and metabolic reprogramming. Large-scale studies, such as the comprehensive tumor microbiome analysis by Nejman et al., have demonstrated that distinct cancer types harbor specific microbial signatures, suggesting the presence of tumor-specific microbial ecosystems [57]. Similarly, alterations in salivary microbiota, including differences in Neisseria elongata and Streptococcus mitis, have been reported in pancreatic cancer patients compared with healthy controls, supporting the diagnostic potential of oral microbial profiling [58]. Oral bacteria may also serve as biomarkers for cancers located outside the oral cavity. Periodontal pathogens such as Fusobacterium nucleatum and Porphyromonas gingivalis have been implicated in colorectal cancer, where they may translocate from the oral cavity to the intestine via swallowing, inhalation, or hematogenous and lymphatic routes. Once established in the gut, these bacteria may contribute to microbial imbalance, chronic inflammation, and the formation of an immunosuppressive tumor microenvironment, thereby promoting colorectal carcinogenesis [59–61]. These findings suggest that oral microbiota profiling may have potential utility in personalized cancer risk assessment and prognostic stratification. Several interconnected mechanisms have been proposed to explain the role of oral microbiota in carcinogenesis, including: (i) induction of chronic inflammation; (ii) disruption of the cell cycle and apoptotic pathways through altered signaling; (iii) production of genotoxic and carcinogenic metabolites, such as reactive oxygen and nitrogen species, nitrosamines, acetaldehyde, and secondary bile acids; and (iv) modulation of host immune responses [62]. Collectively, these findings support the concept that oral microbiome dysbiosis may actively contribute to oral carcinogenesis. Identification of tumor-associated microbial signatures may therefore provide novel opportunities for early diagnosis, risk stratification, and microbiome-targeted therapeutic strategies in OCC. The principal oral microorganisms implicated in OCC carcinogenesis, together with their proposed molecular mechanisms and clinical implications, are summarized in Table 2. Table 2Key oral microbes implicated in OCC carcinogenesisSpeciesMechanismPathwayClinical implicationFusobacterium nucleatumPromotes chronic inflammation, epithelial–mesenchymal transition (EMT), DNA damage, and immune evasionNF-κB, E-cadherin/β-catenin, Ku70/p53Associated with tumor progression, invasiveness, poor radiotherapy response, and unfavorable prognosisPorphyromonas gingivalisInhibits apoptosis, enhances proliferation and immune escape, induces chronic inflammationTLR, NF-κB, MAPK, ROS-related signalingPotential biomarker and therapeutic target in OCCPrevotella intermediaSustains inflammatory microenvironment and dysbiosisPro-inflammatory cytokine signalingAssociated with malignant transformation and OSCC progressionPeptostreptococcus stomatisContributes to tumor-associated dysbiosis and inflammatory signalingLPS-associated pathwaysEnriched in tumor tissues; possible diagnostic biomarkerStreptococcus mutansInduces IL-6–mediated inflammatory signaling and promotes invasive phenotypeIL-6 signalingAssociated with advanced clinical stage and poor disease controlCapnocytophaga leadbetteriContributes to microbial imbalance and inflammatory niche formationNot fully elucidatedIncreased abundance in OSCC tissuesAggregatibacter segnisMay participate in dysbiotic microbial interactionsInflammatory signaling pathwaysIncreased abundance in OSCC-associated microbiotaParvimonas spp.Associated with anaerobic tumor-promoting microenvironmentImmune and inflammatory modulationPotential component of tumor-specific microbial signaturesPeptostreptococcus spp.Promotes chronic inflammation and altered host immunityCytokine-mediated pathwaysPotential biomarker of OCC-associated dysbiosisRothia sp.Potential protective role against carcinogenesisMetabolic modulation pathwaysLower OCC risk observed in Mendelian randomization analysesClostridialesAssociated with protective metabolic interactionsHost metabolome regulationPotentially protective against OCC development Key oral microbes implicated in OCC carcinogenesis Chronic Inflammation and Cancer A strong association exists between chronic inflammation and the development of various human cancers, including OCC. The oral microbiome plays a key role in modulating pro-inflammatory mediators that may promote tumor initiation and progression. Activation of specific transcription factors can upregulate genes involved both in the production of inflammatory mediators and in the regulation of cancer cell survival and proliferation, thereby promoting angiogenesis, immune evasion, and metastasis [63]. Periodontitis, characterized by chronic inflammation and immune dysregulation, has been significantly associated with the initiation and progression of multiple cancers, particularly OCC. This relationship is supported by elevated levels of pro-inflammatory cytokines, including IL-1α, IL-1β, TNF-α, and IL-6, which contribute to tissue damage and disease progression [64]. These cytokines can induce genetic mutations, promote genomic instability, and influence epigenetic modifications, thereby facilitating carcinogenesis. In addition, they contribute to dysregulation of apoptosis, enhanced angiogenesis, and disruption of normal inflammatory signaling pathways. Microbial factors further contribute to this process. Bacterial species such as Fusobacterium nucleatum and Porphyromonas gingivalis can activate key signaling pathways, including NF-κB, in oral epithelial cells, leading to sustained inflammatory responses. In particular, P. gingivalis has been shown to upregulate genes involved in Toll-like receptor (TLR), NF-κB, and MAPK signaling pathways, thereby amplifying the pro-inflammatory immune response in both normal and malignant oral epithelial cells [65]. Moreover, Milward et al. demonstrated that periodontitis-associated bacteria, including P. gingivalis and F. nucleatum, can induce pro-inflammatory responses in keratinocytes, resulting in increased cytokine transcription and protein production in vitro [66]. Causal Roles for Specific Oral Microbes and Metabolites in OCC etiology Emerging evidence suggests that tumor-associated microbiota may actively participate in epithelial transformation and tumor progression rather than merely reflecting local tissue alterations. Lian et al. investigated the potential causal role of oral microbiota, circulating metabolites, and inflammatory proteins in OCC development by analyzing 43 oral microbial taxa, 1400 circulating metabolites, and 91 inflammatory proteins. The authors identified significant associations between OCC risk and 60 metabolites, including glycohyocholate, which was associated with increased risk, and 16α-hydroxy DHEAS-3-sulfate, which demonstrated a protective effect. Additionally, two inflammatory proteins were associated with OCC risk, namely Cystatin D (OR = 1.26) and MCP-1 (OR = 0.69). Among microbial taxa, Clostridiales (OR = 0.89) and Rothia sp. ASV0016 (OR = 0.91) exhibited protective effects, whereas Bacteroidales was associated with increased OCC risk (OR = 1.09). Furthermore, metabolites such as 5α-androstan-3α,17β-diol disulfate and carboxyethyl-GABA appeared to mediate the protective effects of Clostridiales and Rothia sp., respectively [67]. These findings support a complex interaction between oral microbiota, host metabolism, and inflammatory signaling pathways in OCC carcinogenesis. Zhang et al. [68] evaluated 50 patients with OSCC and compared the microbiota compositions obtained from non-tumor and tumor sites using the 16S rDNA sequencing. Tumor sites exhibited richness and diversity of bacteria compared to the control tissues. Six families (Prevotellaceae, Fusobacteriaceae, Flavobacteriaceae, Lachnospiraceae, Peptostreptococcaceae, and Campylobacteraceae) and 13 genera, including Fusobacterium, Alloprevotella and Porphyromonas were presented in cancer tissues. A possible link between these bacteria and OSCC were found at the species level: the abundances of F. nucleatum, Prevotella intermedia, Aggregatibacter segnis, Capnocytophaga leadbetteri, Peptostreptococcus stomatis, and another five species were significantly increased. Furthermore, the functional prediction revealed that genes involved in bacterial chemotaxis, flagellar assembly and lipopolysaccharide (LPS) biosynthesis which are associated with various pathological processes, were significantly increased in the OSCC group. Oral bacterial profiles of OSCC might be considered as a diagnostic markers and treatment targets. The authors suggest that that recolonization of bacteria may lead to disturbance of the unique balance between the inhabitant oral microbiota and the host. This may be a crucial tie through how commensal oral bacteria promote OCC. P. gingivalis, a prominent oral pathogen has been linked with oro-digestive cancer as it exhibits tumorigenic activities, increased oral cancer invasion, and proliferation of OCC stem cells [69]. P. gingivalis is a putative periodontal pathogen, and an etiologic agent of periodontitis which shows expression of a variety of virulence factors and might contribute to carcinogenesis and immune evasion. After infection with P. gingivalis, B7-H1 and B7-DC receptors are up-regulated. The up-regulation of the B7-H1 receptors in host cells result in the chronicity of inflammatory disorders that often forego the development of human cancers. B7-H1 expression leads to anergy and apoptosis of activated T cells, and allowing tumor cells to conquer host response [70]. Moreover, P. gingivalis affects the expression of B7-H1 and B7-DC receptors on the surface of gingival epithelial cells and squamous cell carcinoma cells in mechanism of its induction [71]. P. gingivalis also inhibits apoptosis and oxidative-stress through extracellular-ATP (eATP)-mediated reactive-oxygen-species (ROS) production via phosphorylating Heat Shock Protein 27 (HSp27) with the bacterial enzyme-like nucleoside-diphosphate-kinase (Ndk), which is the effector protein produced by intracellular P. gingivalis [72]. Moreover, NdK effects on extracellular ATP and inhibits its connection with purinergic receptor-7 in order to inhibit ATP-dependent cell apoptosis and disturb normal cell cycle to promote cancerogenesis [73]. Differential microbiota and metabolites in cancer tissues and saliva from OSCC patients, suggesting an association between some microbiota/metabolite such as Fusobacterium or mannose and OSCC [74]. Evidence suggest that Fusobacteria is major pro-tumorigenic oral bacteria associated with epithelial-derived malignancies through modulating oral carcinogenesis and promotion of cancer progression. This Gram‐negative, obligate anaerobic bacteria typically inhabit the periodontium of the oral cavity, gastrointestinal tract, and female genital tract are associated with colorectal tumors by modulating the Wnt/β-catenin pathway [75]. Fusobacteria are linked with the initiation and progression of oral cancer and could potentially enhance cancer cell invasiveness, survival, and epithelial-mesenchymal transition (EMT) when presented in the oral tumor microenvironment [76]. F. nucleatum causes DNA damage and could increase the proliferation of OSCC specifically by E-cadherin/β-catenin pathway and Ku70/p53 pathway. In the future, targeting the CDH1/β-catenin pathway may become a therapeutic approach [77]. F. nucleatum, is an important inflammatory contributor to tumorigenesis progression in OSCC [78]. Introduction of antibiotic metronidazole in colon cancer treatment led to reduced Fusobacterium load, cancer cell proliferation, and overall tumor growth in mice [79]. The presence of Strepetoccus mutans (S. mutans) is associated with the development of OSCC and with advanced clinical stage, poor disease control and elevated invasive OCC incidence. It is suggested that improvement in oral hygiene in order to eradicate S. mutans or targeting IL-6 signaling could be a promising and profitable strategy for OCC associated with S.mutans infection [80]. Microbiome and Radiotherapy and Chemotherapy Maintaining a balanced oral microbiome is crucial for optimizing oncological treatment outcomes, given the complex interactions between microbial communities and therapeutic agents. Radiotherapy can disrupt the microbiota by damaging mucosal integrity and altering immune responses, thereby contributing to both local and systemic toxicity [81]. Oh et al. conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Limosilactobacillus reuteri in patients with HNC undergoing radiotherapy (≥ 60 Gy), with or without concurrent chemotherapy. The study demonstrated that L. reuteri was safe and associated with a reduced incidence and severity of oral mucositis in patients receiving radiotherapy alone [82]. More broadly, microbiota-targeted interventions—including probiotics, prebiotics, and dietary strategies—may mitigate radiotherapy-related toxicity and improve clinical outcomes [82, 83]. Emerging evidence further indicates that the oral microbiome, in conjunction with the gut microbiota, can influence both the efficacy and prognosis of radiotherapy [84]. Preclinical studies using 16S rRNA sequencing have shown that alterations in the oral microbiota may modulate tumor-associated gut microbial composition without affecting adjacent peritumoral tissues. Notably, translocation of buccal Fusobacterium nucleatum has been associated with reduced radiotherapy efficacy and poorer prognosis, while metronidazole administration may counteract these adverse effects. In addition, probiotic supplementation has been shown to enhance immune responses and reduce the severity of oral mucositis in patients undergoing concurrent radiochemotherapy, likely through modulation of treatment-disrupted gut microbiota [85]. Consistently, shifts in the oral microbiome—particularly increased abundance of Fusobacterium—have been correlated with the severity of radiotherapy-induced mucositis [86]. Wu et al. [87] demonstrated that berberine alleviates 5-FU–induced mucosal injury by modulating the microbiota and regulating the PI3K/AKT/mTOR signaling pathway, without compromising antitumor efficacy. These findings highlight the role of the microbiome in influencing both the metabolism and therapeutic effectiveness of chemotherapeutic agents. Significant alterations in the oral microbiota have also been observed in patients undergoing chemotherapy or combined chemo–immunotherapy. Chemotherapy alone was associated with an increased relative abundance of Streptococcus, Gemella, and Granulicatella, alongside a reduction in Neisseria and Veillonella. In contrast, combined chemo–immunotherapy induced a more heterogeneous microbial response. A marked reduction in microbial richness and diversity following treatment underscores the substantial impact of these therapies on the oral microbiome and their contribution to complications such as oral mucositis. These findings emphasize the importance of incorporating microbiome monitoring into oncologic care to better understand treatment-induced microbial shifts. Integrating microbiome surveillance into clinical practice may open new avenues for advancing precision oncology, enabling the development of targeted strategies to restore microbial balance, improve treatment tolerance, and reduce therapy-related toxicities. Current microbiome-based therapeutic and preventive strategies investigated in OCC are summarized in Table 3. Table 3Microbiome-based therapeutic strategies in OCCStrategyEvidenceClinical settingLimitationsProbiotics (Limosilactobacillus reuteri)Randomized placebo-controlled trial demonstrated reduced oral mucositis severityRadiotherapy-induced oral mucositis in HNCLimited number of clinical trials; lack of long-term outcome dataPrebiotics and dietary interventionsEmerging translational and clinical evidence suggests microbiome stabilization and reduced toxicitySupportive care during radiotherapy and chemotherapyLack of standardized protocols and heterogeneous study designsAntibiotic therapy (e.g., metronidazole)Preclinical studies showed reduction of F. nucleatum burden and tumor growthExperimental microbiome-targeted cancer therapyRisk of dysbiosis, antimicrobial resistance, and off-target microbial depletionSalivary microbiome profilingIncreasing evidence for diagnostic and prognostic applicationsEarly detection, risk stratification, treatment monitoringLack of validated biomarkers and standardizationMicrobiome surveillance during oncologic therapyObservational studies demonstrated therapy-associated microbial shiftsPrecision oncology and toxicity monitoringLimited integration into clinical workflowsFecal microbiota modulationExperimental evidence supports systemic immune modulation through oral–gut axisImmunomodulation and supportive cancer careInsufficient OCC-specific clinical evidenceEngineered bacteriotherapyEarly translational and preclinical studiesPrecision microbiome-targeted therapeuticsExperimental stage; safety and regulatory concernsInnate immune reprogramming through microbiome modulationEmerging mechanistic evidenceEnhancement of antitumor immunityLimited clinical validationCytokine-targeted approaches linked to microbiotaPreclinical evidence suggests benefit through inflammatory pathway modulationPersonalized anti-inflammatory strategiesBiomarker selection and patient stratification remain unclearOral hygiene and periodontal treatmentEpidemiological and mechanistic evidence linking periodontitis with OCCPrevention and supportive careDifficult to quantify direct oncologic benefit Microbiome-based therapeutic strategies in OCC The integration of microbiome surveillance into clinical practice may open new avenues for the advancement of precision oncology. Cancer therapy significantly impacts the oral microbiome, thereby creating opportunities for precision-based strategies aimed at restoring microbial balance and reducing treatment-related complications [88, 89]. Looking Forward The advent of modern sequencing technologies, including recent advances in metagenomic analyses and salivary metabolomics, has revolutionized our understanding of the human microbiome [90]. These approaches enable the identification of salivary biomarkers—such as IL-6, specific miRNA signatures, and microbial profiles—which may be valuable for the early detection and monitoring of OCC. Salivary biomarkers (DNA, RNA and protein markers) are promising diagnostic and prognostic tool in OCC diagnosis, treatment and prognosis. As the saliva has a direct contact with oral cancer lesions, it makes salivary biomarkers sensitive and specific, screening method in diagnosis, staging and follow-up. Salivary biomarkers include proteomic, transcriptomic, and metabolomic biomarkers. Saliva samples are easily accessible, non-invasive and safe to handle and delivers data regarding oral microbial ecosystem. Salivary biomarkers in OSCC include: peptides: salivary defensin-1, proteins: interleukins (8, 6, 1β), matrix metalloproteinase (MMP 2, 9), transforming growth factor (TGF-1), Ki67, cyclic D1, Cyfra 21.1, transferrin, α amylase, tumor necrosis factor (TNF-α), CD44; DNA: p53 mutations and aberrant methylation of p16, MGMT and DAP-K; salivary mRNAs: DUSP1, H3F3A, IL 1B, IL 8, SAT and S100; DUSP1 (dual specificity phosphatase 1); H3 histone family 3 A (H3F3A); Interleukin 1 beta (IL IB); Interleukin 8 (IL 8); Spermidine/spermine N1-acetyltransferase 1; S100 calcium binding protein P (S100 P); salivary microRNA: miR-125a, miR-200a, miR-31. Salivary biomarker analysis for OCC may provide important information for understanding its genomic architecture [91]. These biomarkers may be used in a non-invasive diagnostic for screening and early detection of OSCC identifying key metabolites that differentiate malignant from non-malignant lesions. Oral microbiota may be used in a personalized medicine approach that aims to provide tailor-made prevention and treatment strategies. It may serve as both a diagnostic tool and a therapeutic target. A comprehensive evaluation consisting of an assessment of the microbiome combined with personalized microbiota interventions along with genetic and immune analysis will allow for the development of an individualized treatment plan based on the unique microbiological and immunological status of the patient. Identifying specific microbial profiles associated with increased cancer risk will allow for the development of specific therapeutic strategies aimed at reducing pathogenic bacteria, restoring microbial balance, and modulating the immune response. Such a multi-layered, individualized approach in the future may be used for prevention and treatment of oral dysbiosis consistently leading to overall oral health outcomes improvement [92]. Novel insights into the microbial ecology of radiotherapy-treated HNC patients may lead to individualized approach for microbial-targeted therapies in its prevention and treatment. It was revealed that such patients showed lower microbiota diversity and the dental biofilm. RT patients showed lower microbiota diversity and their dental biofilm presented noticeable alterations in microbiome composition compared to no RT patients, including enrichment of acidogenic species and changed metabolic potential [93]. Utilization of selectively targeting transcription pathways including NF-κB, cytokines or cell types known to contribute to the inflammatory secretome, may enable an opportunity to target inflammation in order to improve patient outcomes. Especially the salivary cytokines could be used for diagnostic and prognostic aims in patients with oral cancer [94]. Microbiome-modulating therapies tailored to the patient's individual profile and aimed at improving cancer treatment outcomes are also being introduced, including the introduction of antibiotics to reduce harmful bacteria. Furthermore, the inclusion of probiotics and prebiotics to enhance beneficial bacteria is a strategy to restore a healthy microbiome, including fecal microbiome [95]. The translocation and communication of flora between the oral cavity and the gut may result from the impairment of the gut-oral barrier. Oral and intestinal microorganisms have been shown to interact through entero-oral and fecal–oral pathways, which in turn can create and/or transform microbial ecosystems in both habitats, ultimately regulating physiological and pathological processes in the body. Analysis of the microbial composition of the oral cavity, colonic mucosa, and stool samples collected from patients with colon cancer revealed a close association of several oral bacteria with colon cancer. This suggests that interplay between microorganisms may also be an important mechanism of carcinogenesis in the gastrointestinal tract [96–101]. Engineered bacteriotherapy, microbiome-targeted immunomodulators, and microbiota-based diagnostics are expanding therapeutic options for OCC patients and, when combined with advances in precision medicine, may facilitate personalized treatment approaches in order to improve patient’s treatment results [102]. Targeting microbiota modulation or innate immune reprogramming represents a promising strategy for restoring anti-tumor immunity and enhancing therapeutic efficacy in OCC. Microbiota modulation and innate immune reprogramming offer promising avenues to restore antitumor immunity and improve treatment efficacy in OCC [103–106]. Conclusions Identification of novel biomarkers within oral microbiota communities and the development of microbiota-targeted therapeutic strategies may become key components of future OCC diagnosis and treatment. Prevention protocols should emphasize the improvement of oral hygiene as a critical measure in preventing and managing periodontitis. Additionally, interventions targeting the oral microbiota—such as probiotics, prebiotics, and dietary modifications—have the potential to reduce radiotherapy-related toxicity, thereby improving patient outcomes. References of Outstanding Importance Bruno JS, Heidrich V, Restini FCF, Alves TMMT, Miranda-Silva W, Knebel FH, Cóser EM, Inoue LT, Asprino PF, Camargo AA, Fregnani ER. Dental biofilm serves as an ecological reservoir of acidogenic pathobionts in head and neck cancer patients with radiotherapy-related caries. mSphere. 2025 Jun 30:e0025725. https://doi.org/10.1128/msphere.00257-25.◦ the critical importance of oral health education and care for individuals with head and neck cancer patients undergoing radiotherapy, authors advocate for the prescription of fluoride products to promote the formation of pH-resistant fluorapatite. Bruno JS, Heidrich V, Restini FCF, Alves TMMT, Miranda-Silva W, Knebel FH, Cóser EM, Inoue LT, Asprino PF, Camargo AA, Fregnani ER. Dental biofilm serves as an ecological reservoir of acidogenic pathobionts in head and neck cancer patients with radiotherapy-related caries. mSphere. 2025 Jun 30:e0025725. https://doi.org/10.1128/msphere.00257-25.◦ the critical importance of oral health education and care for individuals with head and neck cancer patients undergoing radiotherapy, authors advocate for the prescription of fluoride products to promote the formation of pH-resistant fluorapatite. ◦ the critical importance of oral health education and care for individuals with head and neck cancer patients undergoing radiotherapy, authors advocate for the prescription of fluoride products to promote the formation of pH-resistant fluorapatite. ◦ the critical importance of oral health education and care for individuals with head and neck cancer patients undergoing radiotherapy, authors advocate for the prescription of fluoride products to promote the formation of pH-resistant fluorapatite. Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati ST, Kazemi KS, Nabi Afjadi M. Exploring the role of oral bacteria in oral cancer: a narrative review. Discov Oncol. 2025 Feb 26;16(1):242. https://doi.org/10.1007/s12672-025-01998-2.◦ some species, such as Salmonella typhimurium and Clostridium spp., are being explored as possible cancer treatment vectors. Thus, understanding these microbial interactions highlights the importance of maintaining a healthy oral microbiome in preventing OCCs. Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati ST, Kazemi KS, Nabi Afjadi M. Exploring the role of oral bacteria in oral cancer: a narrative review. Discov Oncol. 2025 Feb 26;16(1):242. https://doi.org/10.1007/s12672-025-01998-2.◦ some species, such as Salmonella typhimurium and Clostridium spp., are being explored as possible cancer treatment vectors. Thus, understanding these microbial interactions highlights the importance of maintaining a healthy oral microbiome in preventing OCCs. ◦ some species, such as Salmonella typhimurium and Clostridium spp., are being explored as possible cancer treatment vectors. Thus, understanding these microbial interactions highlights the importance of maintaining a healthy oral microbiome in preventing OCCs. ◦ some species, such as Salmonella typhimurium and Clostridium spp., are being explored as possible cancer treatment vectors. Thus, understanding these microbial interactions highlights the importance of maintaining a healthy oral microbiome in preventing OCCs. Ahmad S, Jayamanne D, Bergamin S, Lawless A, Guminski A, Lee A, Yuile A, Wheeler H, Eade T, Back M, Molloy M, Oh B. Oral Microbiome as a Biomarker and Therapeutic Target in Head and Neck Cancer: Current Insights and Future Directions. Cancers (Basel). 2025 Aug 15;17(16):2667. https://doi.org/10.3390/cancers17162667.◦ authors emphasize distinct alterations in oral microbiome diversity and composition among head and neck cancer patients, highlighting the role of microbial dysbiosis in cancer progression. Standardized protocols for oral sample collection and microbiota analysis are essential to facilitate more robust, comparable, and clinically meaningful research outcomes. Ahmad S, Jayamanne D, Bergamin S, Lawless A, Guminski A, Lee A, Yuile A, Wheeler H, Eade T, Back M, Molloy M, Oh B. Oral Microbiome as a Biomarker and Therapeutic Target in Head and Neck Cancer: Current Insights and Future Directions. Cancers (Basel). 2025 Aug 15;17(16):2667. https://doi.org/10.3390/cancers17162667.◦ authors emphasize distinct alterations in oral microbiome diversity and composition among head and neck cancer patients, highlighting the role of microbial dysbiosis in cancer progression. Standardized protocols for oral sample collection and microbiota analysis are essential to facilitate more robust, comparable, and clinically meaningful research outcomes. ◦ authors emphasize distinct alterations in oral microbiome diversity and composition among head and neck cancer patients, highlighting the role of microbial dysbiosis in cancer progression. Standardized protocols for oral sample collection and microbiota analysis are essential to facilitate more robust, comparable, and clinically meaningful research outcomes. ◦ authors emphasize distinct alterations in oral microbiome diversity and composition among head and neck cancer patients, highlighting the role of microbial dysbiosis in cancer progression. Standardized protocols for oral sample collection and microbiota analysis are essential to facilitate more robust, comparable, and clinically meaningful research outcomes. Xia Q, Pierson S. HPV Infection and Oral Microbiota: Interactions and Future Implications. Int J Mol Sci. 2025 Feb 8;26(4):1424. https://doi.org/10.3390/ijms26041424. PMID: 40003891; PMCID: PMC11855562.◦ the interaction between HPV and oral microbiota represents a promising area of research that could revolutionize the prevention, diagnosis, and treatment of HPV-related oral cancers. Xia Q, Pierson S. HPV Infection and Oral Microbiota: Interactions and Future Implications. Int J Mol Sci. 2025 Feb 8;26(4):1424. https://doi.org/10.3390/ijms26041424. PMID: 40003891; PMCID: PMC11855562.◦ the interaction between HPV and oral microbiota represents a promising area of research that could revolutionize the prevention, diagnosis, and treatment of HPV-related oral cancers. ◦ the interaction between HPV and oral microbiota represents a promising area of research that could revolutionize the prevention, diagnosis, and treatment of HPV-related oral cancers. ◦ the interaction between HPV and oral microbiota represents a promising area of research that could revolutionize the prevention, diagnosis, and treatment of HPV-related oral cancers. Lian Q, Dong L, Zhou Q, Yuan Q. Effect of the oral microbiota, blood metabolome, and inflammatory proteins on oral cavity cancer: A bidirectional two-sample Mendelian randomization study and mediation analysis. J Stomatol Oral Maxillofac Surg. 2025 Oct;126(5):102372. https://doi.org/10.1016/j.jormas.2025.102372. Epub 2025 Apr 15. PMID: 40246198.◦ genetic evidence supporting causal roles for specific oral microbes and metabolites in OCC etiology, mechanistic insights into the 'oral microbiome-host metabolism' axis, possible biomarkers for early detection and risk assessment, identifying potential preventative or therapeutic targets. Lian Q, Dong L, Zhou Q, Yuan Q. Effect of the oral microbiota, blood metabolome, and inflammatory proteins on oral cavity cancer: A bidirectional two-sample Mendelian randomization study and mediation analysis. J Stomatol Oral Maxillofac Surg. 2025 Oct;126(5):102372. https://doi.org/10.1016/j.jormas.2025.102372. Epub 2025 Apr 15. PMID: 40246198.◦ genetic evidence supporting causal roles for specific oral microbes and metabolites in OCC etiology, mechanistic insights into the 'oral microbiome-host metabolism' axis, possible biomarkers for early detection and risk assessment, identifying potential preventative or therapeutic targets. ◦ genetic evidence supporting causal roles for specific oral microbes and metabolites in OCC etiology, mechanistic insights into the 'oral microbiome-host metabolism' axis, possible biomarkers for early detection and risk assessment, identifying potential preventative or therapeutic targets. ◦ genetic evidence supporting causal roles for specific oral microbes and metabolites in OCC etiology, mechanistic insights into the 'oral microbiome-host metabolism' axis, possible biomarkers for early detection and risk assessment, identifying potential preventative or therapeutic targets. Pitashny M, Kesten I, Shlon D, Hur DB, Bar-Yoseph H. The Future of Microbiome Therapeutics. Drugs. 2025 Feb;85(2):117–125. https://doi.org/10.1007/s40265-024-02107-3. Epub 2025 Jan 23. PMID: 39843757; PMCID: PMC11802617.◦ advancements in technology are paving the way for the development of novel microbiome therapeutics, across a wide range of indications. Pitashny M, Kesten I, Shlon D, Hur DB, Bar-Yoseph H. The Future of Microbiome Therapeutics. Drugs. 2025 Feb;85(2):117–125. https://doi.org/10.1007/s40265-024-02107-3. Epub 2025 Jan 23. PMID: 39843757; PMCID: PMC11802617.◦ advancements in technology are paving the way for the development of novel microbiome therapeutics, across a wide range of indications. ◦ advancements in technology are paving the way for the development of novel microbiome therapeutics, across a wide range of indications. ◦ advancements in technology are paving the way for the development of novel microbiome therapeutics, across a wide range of indications. Author Contributions K.P.-Z. and K.D. M. K., A. L created the concepts. All authors contributed to the study conception and design. K.P.-Z. analyzed the literature and drafted the manuscript. K. D., A.L, K.P. Z. drafted the manuscript and figures. K.P.-Z., K.D., K. P., and T. Z. designed the project and coordinated the preparation of the manuscript. K.P.-Z., K.D., K.P., T. Z, A. L and M.K. critically revised the manuscript. All authors approved the final manuscript. Funding The author(s) declare that financial support was received for the research and/or publication of this article. This article was prepared within the framework of the topic “Assessment of the microbiome in oral cancers” task recorded in the SIMPLE system: SUBK.C250.25.065, financed by the Wroclaw Medical University. Data Availability No datasets were generated or analysed during the current study. Declarations Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.